Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

<p>Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-</p>

保存先:

書誌詳細
第一著者:	Erwin Tomasich (15052256) (author)
その他の著者:	Ariane Steindl (15022655) (author), Christina Paiato (15360180) (author), Teresa Hatziioannou (15052262) (author), Markus Kleinberger (15360183) (author), Luzia Berchtold (15360186) (author), Rainer Puhr (15052253) (author), Johannes A. Hainfellner (15360189) (author), Leonhard Müllauer (15118769) (author), Georg Widhalm (15052268) (author), Franziska Eckert (15360192) (author), Rupert Bartsch (15360195) (author), Gerwin Heller (15052250) (author), Matthias Preusser (15017558) (author), Anna Sophie Berghoff (15360198) (author)
出版事項:	2025
主題:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Breast Cancer Clinical-Stage Research Drug Targets Cell surface receptor drug targets Lung Cancer Progression, Invasion & Metastasis Metastasis
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
著者:: Niklas Klümper (15048887)
出版事項: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
著者:: Niklas Klümper (15048887)
出版事項: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
著者:: Yuncheng Bei (16546095)
出版事項: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
著者:: Yuncheng Bei (16546095)
出版事項: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
著者:: Yuncheng Bei (16546095)
出版事項: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
著者:: Sheheryar Kabraji (15050565)
出版事項: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
著者:: Santiago Duro-Sánchez (14959182)
出版事項: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
著者:: Srivandana Akshintala (16610490)
出版事項: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
著者:: Srivandana Akshintala (16610490)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
著者:: Katie E. Hebron (15046889)
出版事項: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
著者:: Katie E. Hebron (15046889)
出版事項: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
著者:: Katie E. Hebron (15046889)
出版事項: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
著者:: Katie E. Hebron (15046889)
出版事項: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
著者:: Katie E. Hebron (15046889)
出版事項: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
著者:: Katie E. Hebron (15046889)
出版事項: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
著者:: Katie E. Hebron (15046889)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3c48p9klsfa2hb3da5ds29a6be